GDP Issues cited in Non-Compliance Report
Recommendation
22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
A new Non-Compliance Report was published on the EudraGMDP site. On 21 September 2017, the Danish Medicines Agency performed an inspection at EuroPharma.DK ApS in Denmark. EuroPharma.DK ApS performs parallel import, repacking and distribution of pharmaceutical products.
During that inspection, it was considered that the secondary packing operations at the site do not comply with Good Manufacturing Practice and that there is a "lack of will and ability to adhere to the principles" of Good Distribution Practices (GDP):
This was also based on the following observations:
- Inadequate control for falsifications and temperature excursions during transportation upon receipt of medicinal products
- Deficient procedures for qualification of transporters/forwarders
As a consequence, the respective manufacturing authorisation was suspended and medicinal products must not be re-packed by EuroPharma DK or any of their contract manufacturers and must not be released and distributed.
Source: EudraGMDP Database (Non-Compliance Reports, Report No: 2017090955)
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September